Trifluridine-Tipiracil

A randomized phase 3 trial designed to compare an investigational combination with standard care for certain patients with advanced colorectal cancer failed to meet its primary endpoint of OS.

MADRID — Sotorasib plus panitumumab prolonged PFS compared with standard of care for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, study results presented at ESMO Congress showed.

The FDA approved trifluridine and tipiracil with bevacizumab for patients with previously treated metastatic colorectal cancer.

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.

The FDA announced several regulatory actions the past few weeks.

In this video interview, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed the SUNLIGHT trial data presented at ASCO Gastrointestinal Cancers Symposium.

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed the mature phase 3 data on the addition of bevacizumab to trifluridine/tipiracil in refractory colorectal cancer in a video interview with Healio.

The addition of bevacizumab to trifluridine/tipiracil demonstrated a statistically significant and clinically meaningful improvement in OS vs. trifluridine/tipiracil alone among adults with refractory metastatic colorectal cancer.

The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.

In a meta-analysis of triluridine/tipiracil (TAS-102) plus bevacizumab triluridine/tipiracil alone, there was a benefit to adding bevacizumab for patients with lateline colorectal cancer that is metastatic.